Bronchiectasis: Optimising Azithromycin prevention Treatment to reduce exacerbations (BOAT): A double blind pragmatic 2 arm phase IV randomised controlled trial
Research summary
This is a randomised,double-blind,non-inferiority,pragmatic trial comparing continued azithromycin prophylaxis (standard care) with its complete discontinuation in adults with stable bronchiectasis at high risk of exacerbations. Participants (n=1,000) will be allocated 1:1 via a web-based system across 50–60 UK centres,with a median follow-up of ~24 months. The event-driven design aims to observe 846 primary events. The primary objective is to determine whether discontinuing azithromycin is non-inferior to continued use regarding time to first exacerbation (TTFE). Secondary objectives include assessing exacerbation frequency and severity,quality of life,hospitalisations,mortality,adverse events,subgroup responses,cost-effectiveness,and treatment adherence. The principal hypothesis is that stopping azithromycin is non-inferior to continuing it for TTFE and may offer long-term benefits such as reduced antibiotic resistance and adverse effects.
Principal Investigator
Dr William Flowers
Contact us
Email: samantha.chilcott@ndm.ox.ac.uk
IRAS number
1010479